The unique metabolic properties of leukemia stem cells are proving to be their Achilles’ heel

Acute myeloid leukemia (AML) is characterized by an expansion of abnormal undifferentiated myeloblast due to an acquired mutation in blood-forming cells from the bone marrow, resulting in impaired hematopoiesis. The typical treatment for AML is induction chemotherapy but refractory disease is common, and relapse can occur causing initial and subsequent treatments to fail. This is